Table 1.
Baseline characteristics
| Vitamin D | Placebo | |
|---|---|---|
| n=13 | n=14 | |
| Age (years) | 56 (10) | 57 (9) |
| Female | 10 (77) | 9 (64) |
| Ethnicity | ||
| European | 10 (77) | 9 (64) |
| Indian | 1 (8) | 3 (21) |
| Other | 1 (8) | 2 (14) |
| Weight (kg) | 75 (19) | 72 (13) |
| Dietary calcium intake (mg/day) | 730 (670) | 660 (330) |
| Smoking status | ||
| Current | 3 (23) | 0 (0) |
| Never smoked | 8 (63) | 9 (64) |
| Glucocorticoid use | ||
| Past oral use | 7 (54) | 9 (64) |
| Current oral use | 1 (8) | 0 (0) |
| Current inhaled use | 6 (46) | 1 (7) |
| Sarcoidosis extent | ||
| Pulmonary involvement | 11 (85) | 8 (57) |
| Extrapulmonary involvement | 6 (46) | 7 (50) |
| Chest radiograph stage at baseline | ||
| 0 | 1 (10) | 6 (46) |
| 1 | 1 (10) | 1 (8) |
| 2 | 1 (10) | 0 (0) |
| 3 | 3 (30) | 4 (31) |
| 4 | 4 (40) | 2 (15) |
| Bone density (g/cm2) | ||
| Lumbar spine | 1.16 (0.19) | 1.13 (0.11) |
| T score | −0.2 (1.6) | −0.6 (0.9) |
| Total hip | 0.95 (0.11) | 0.93 (0.11) |
| T score | −0.6 (0.9) | −0.8 (0.9) |
| Femoral neck | 0.89 (0.13) | 0.91 (0.09) |
| T score | −1.2 (1.0) | −0.9 (0.7) |
| Total body | 1.15 (0.10) | 1.11 (0.07) |
| Adjusted serum calcium (mmol/L) | 2.24 (0.06) | 2.26 (0.12) |
| Serum phosphate (mmol/L) | 1.23 (0.15) | 1.06 (0.17) |
| Serum creatinine (mmol/L) | 74 (14) | 77 (12) |
| 24 h urine calcium (mmol/day) | 4.6 (3.4) | 6.6 (5.2) |
| Screening 25-hydroxyvitamin D (nmol/L)* | 35 (12) | 38 (9) |
| Baseline 25-hydroxyvitamin D (nmol/L)* | 40 (17) | 45 (17) |
| 1,25-dihydroxyvitamin D (pmol/L) | 109 (34) | 116 (25) |
| Parathyroid hormone (pmol/L) | 4.0 (1.6) | 4.9 (2.0) |
| P1NP (ug/L) | 37 (12) | 40 (15) |
| β-CTX (ng/L) | 310 (130) | 360 (210) |
*25-Hydroxyvitamin D were measured at the screening study visit using a Diasorin assay, while the baseline 25-hydroxyvitamin D at the first study visit (average 3 weeks later) were stored frozen until the end of the study and then measured with a liquid chromatography tandem mass spectrometry assay (see text). Data are mean (SD) or n (%).
P1NP, serum procollagen type-I N-terminal propeptide; β-CTX, serum β-C-terminal telopeptide of type I collagen.